Blood markers for predicting DLBCL treatment response
Part of Blood & lymphatic, Cancer clinical trials.
This study looks at how certain blood tests (like CRP, albumin, and their ratios) might help predict how well treatment works for newly diagnosed DLBCL. If you are getting R-CHOP, this trial could help doctors better understand your response to therapy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 65 years old.
- You have been diagnosed with diffuse large B-cell lymphoma (DLBCL) and have not yet received any treatment for it.
- Your doctor plans to treat you with the standard chemotherapy combination called R-CHOP.
- You are in generally good health, able to take care of yourself and do light activities (ECOG 0-2).
- You do not have any other current or past cancers, and you do not have uncontrolled medical conditions like diabetes, autoimmune disease, or active infection.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at the biology of certain lymphomas to better understand why some people respond well to treatment and others don't. It involves giving a small additional blood or tissue sample to help researchers find genetic clues that could improve future care.
This trial uses a blood test to look for tumor DNA in people with high-risk B-cell lymphoma, to help predict if the lymphoma might spread to the brain or spinal cord. It may help doctors decide on extra treatments to prevent that spread.
This trial tests two different drug combinations to see which is better for people with a type of lymphoma that has certain genetic markers. It aims to improve outcomes for patients who have not received treatment before.
This trial is for people with newly diagnosed DLBCL who have a specific blood marker before treatment and achieve complete remission after standard chemotherapy. The study uses a blood test to help guide whether additional treatment is needed after chemotherapy.
This study looks at whether a blood test can help doctors understand and monitor large B-cell lymphoma during treatment. It may help guide decisions about your care.
This trial studies whether using a blood test (ctDNA) can help guide treatment decisions for people with newly diagnosed diffuse large B-cell lymphoma. It tests standard chemotherapy regimens (R-CHOP or R-pola-CHP) and aims to improve outcomes by monitoring tumor DNA in the blood.
Hear when a new DLBCL - Diffuse Large B Cell Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.